|
03 Apr 2019 |
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
|
|
03 Apr 2019 |
Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
|
|
03 Apr 2019 |
Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
|
|
03 Apr 2019 |
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
|
|
03 Apr 2019 |
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
|
|
02 Apr 2019 |
Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting
|
|
02 Apr 2019 |
MiNA Therapeutics Presents Pre-Clinical Data Supporting Combination of MTL-CEBPA with Sorafenib and Other Cancer Treatments at AACR
|
|
02 Apr 2019 |
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
|
|
02 Apr 2019 |
Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
|
|
02 Apr 2019 |
Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
|
|
02 Apr 2019 |
Nkarta Therapeutics Presents Data at AACR Demonstrating Proprietary NK Cell Engineering and Expansion Technology Enhances Potency and Cytotoxicity of NK Cells
|
|
02 Apr 2019 |
Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019
|
|
01 Apr 2019 |
Oncorus Presents Preclinical Data Supporting the Advancement of its Lead Oncolytic Virus Therapy Clinical Candidate, ONCR-177
|
|
31 Mar 2019 |
Atara Biotherapeutics Announces Collaborator Presentation of Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma
|
|
30 Mar 2019 |
Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
|
|
30 Mar 2019 |
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype
|
|
30 Mar 2019 |
Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019
|
|
26 Mar 2019 |
Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
|
|
26 Mar 2019 |
Oxford Biomedica notes the Japanese approval of Kymriah® (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia
|
|
21 Mar 2019 |
MolMed received the authorization to start phase I/II clinical investigation with CAR T CD44v6 cells in acute myeloid leukemia and multiple myeloma.
|
|
21 Mar 2019 |
Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials
|
|
20 Mar 2019 |
Trizell Ltd. announces Phase 3 pivotal study of interferon alfa-2b gene therapy in malignant pleural mesothelioma
|
|
19 Mar 2019 |
Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
|
|
14 Mar 2019 |
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
|
|
13 Mar 2019 |
PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment
|
